Waltermire Robert E.
SEC CIK 1876996 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Senior VP, Chief Pharma Dev | 5,789 | — | $11.25M | 20 | 2023-01-16 | 2025-03-05 |
Most active insiders at MDGL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FRIEDMAN PAUL A | Dir | — | $26.66M |
| 2 | Taub Rebecca | Dir | — | $21.68M |
| 3 | Sibold William John | Pres, CEO, Dir | — | $10.48M |
| 4 | BATE KENNETH | Dir | — | $8.03M |
| 5 | Levy Richard S | Dir | — | $7.36M |
| 6 | Dier Mardi | EVP, CFO | — | $3.77M |
| 7 | Huntsman Carole | Chief Commercial Off | — | $1.71M |
| 8 | Soergel David | Chief Medical Off | — | $952.0K |
| 9 | Kelley Shannon T | GC | — | $841.6K |
| 10 | Thakkar Rita | CAO | — | — |
Waltermire Robert E. made no open-market trades at MDGL in the last 12 months.
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-07 | 2025-03-05 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | A - Grant | $0.00 | +2,061 | 5,789 | +55% | $0 |
| DM | 2025-03-07 | 2025-03-05 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $341.33 | -14.1K | 10.9K | -56% | -$4.82M |
| DM | 2025-03-07 | 2025-03-05 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.49 | +14.1K | 17.8K | +379% | +$1.23M |
| M | 2025-03-04 | 2025-02-28 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $341.07 | -1,227 | 3,728 | -25% | -$418.5K |
| 2025-01-27 | 2025-01-24 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $335.24 | -103 | 4,955 | -2% | -$34.5K | |
| 2025-01-17 | 2025-01-17 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $273.41 | -442 | 5,058 | -8% | -$120.8K | |
| D | 2024-06-18 | 2024-06-14 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $280.00 | -1,900 | 5,500 | -26% | -$532.0K |
| D | 2024-06-18 | 2024-06-14 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.09 | +1,900 | 7,400 | +35% | +$165.5K |
| D | 2024-06-14 | 2024-06-12 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $285.00 | -2,000 | 5,500 | -27% | -$570.0K |
| D | 2024-06-14 | 2024-06-12 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +2,000 | 7,500 | +36% | +$175.8K |
| 2024-05-23 | 2024-05-21 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $231.34 | -1,036 | 5,500 | -16% | -$239.7K | |
| D | 2024-01-25 | 2024-01-23 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | A - Grant | $0.00 | +1,419 | 6,536 | +28% | $0 |
| 2024-01-18 | 2024-01-16 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | F - Tax | $243.92 | -550 | 5,117 | -10% | -$134.2K | |
| DM | 2023-12-18 | 2023-12-14+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $235.50 | -4,000 | 6,667 | -37% | -$942.0K |
| DM | 2023-12-18 | 2023-12-14+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +4,000 | 7,667 | +109% | +$351.7K |
| DM | 2023-12-14 | 2023-12-12+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $222.82 | -3,800 | 5,667 | -40% | -$846.7K |
| DM | 2023-12-14 | 2023-12-12+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +3,800 | 8,167 | +87% | +$334.1K |
| DM | 2023-03-02 | 2023-02-28+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +10.0K | 10.7K | +1,499% | +$879.2K |
| DM | 2023-03-02 | 2023-02-28+ | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $273.24 | -10.0K | 9,767 | -51% | -$2.73M |
| 2023-01-18 | 2023-01-16 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Waltermire Robert E. | Senior VP, Chief Pharma Dev | A - Grant | $0.00 | +5,667 | 5,667 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations